@FiercePharma: ICYMI from FiercePharmaManufacturing: UAE drug distributor building a $20M plant in Dubai. Report | Follow @FiercePharma
@EricPFierce: Hospira has now received FDA warning letters for plants on 4 of 7 continents. FiercePharmaManufacturing article | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Shire could use boost from adult ADHD med to hit $10B goal. Report | Follow @CarlyHFierce
> Pfizer's ($PFE) Viagra may be the most effective treatment for erectile dysfunction, but it also has a higher rate of side effects than other options, according to a new analysis. Report
> Pfizer Canada is giving Shoppers Drug Mart credit for alerting the public that expired pills had recently been dispensed. More
> An affiliate of India's Aurobindo Pharma has alleged that former owner of a natural products company it bought out of a U.S. bankruptcy proceeding committed fraud. Report (sub. req.)
> Spain's Laboratorio Reig Jofre has purchased the licenses of four dermatological products in the U.K. from Dema UK. Report
Medical Device News
@FierceMedDev: FDA approves breath test for stomach disorder, highlights its ease of use over standard of care. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: Alere earns FDA clearance for rapid diagnostic of Strep A. FierceDiagnostics story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: AdverseEvents: Analysis of side-effect reports turns up troubling safety signals for Novartis, Eisai drugs. Article | Follow @EmilyWFierce
> FDA recalls fall more than 50% in Q1 2015 after reaching record high in 2014. More
> Study: False alarms of breast cancer costing U.S. $4B a year. Story
> Medtronic debuts European study of its atrial fibrillation device. Article
Biotech News
@FierceBiotech: ICYMI: Nabriva preps for PhIII antibiotic trial with a $120M VC commitment. Story | Follow @FierceBiotech
@JohnCFierce: Alzheimer's startup Alzheon bags $10M and beats a path to Phase III. Article | Follow @JohnCFierce
@DamianFierce: ICYMI: Life sciences entrepreneurs, here is my gift to you: The Biotech Name Generator | Follow @DamianFierce
> Rhythm rolls into Phase IIb with an Actavis buyout in the balance. Report
> Merck (sort of) wins back 'breakthrough' boasting rights on hep C. Article
> Woodford to U.S.: You're in a bubble. We're not. More
Pharma Marketing News
> Next DTC push for Linzess: Spotlight patients, with big salesforce backup. More
> Pfizer, Merck KGaA suit up for Xalkori marketing wave. Report
> Does pricier mean better to ad consumers? FDA means to find out. Article
> Patient portals open door to lasting relationships with patients, 'Digital Doctor' says. Story
> Pfizer wants Canadians to think EpiPen. What else but a hockey partnership? More
Biotech Research News
> Zurich investigators ID pathway for B cell lymphoma. Item
> Berkeley, Harvard groups highlight new targets for cachexia. Report
> Regulus surges after AstraZeneca snags rights to NASH drug. More
> Whitehead team adapts CRISPR-Cas9 tech to target killer fungal infections. Article
> Daiichi Sankyo partners with Sanford-Burnham on a cardio molecule. Story
Diagnostics News
> Researchers develop paper microchip and smartphone diagnostic for HIV. Item
> OpGen eyes $35M IPO for drug-resistant bacteria tests. Story
> Roche and Foundation Medicine seal $1.2B deal with plans for cancer R&D. More
> Alere earns FDA clearance for rapid diagnostic of Strep A. News
> Natera ropes in $55M with eye on cancer Dx. Article
And Finally... Type 2 diabetes patients may have less depression and fewer hunger pains if they eat a big breakfast and lunch rather than 6 smaller meals throughout the day, a new study suggests. More